睿知中国疾病研究地图
候选清单0

即将招募胃癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer

ClinicalTrials.gov 上登记的一项胃癌开放试验,由郑州大学第一附属医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07361991,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed advanced gastric or gastroesophageal junction adenocarcinoma (GC or GEJC).

    入选标准第 4 条

  3. Contraception: Women of childbearing potential and men whose partners are women of childbearing potential must agree to use effective contraception throughout the treatment period and for 6 months after the last dose of study treatment.

    入选标准第 28 条

    Active autoimmune disease requiring systemic treatment (e.g., disease-modifying agents, corticosteroids, or immunosuppressive drugs) within 2 years prior to the first dose of study drug. Replacement therapy (e.g., thyroxine, insulin, or physiological replacement doses of corticosteroids for adrenal or pituitary insufficiency) is not considered systemic treatment.

    排除标准第 18 条

    Unresolved toxicities from prior antitumor therapies > Grade 1 (based on NCI CTCAE), with the exception of the following: persistent Grade 2 alopecia, peripheral neuropathy, hypomagnesemia, or other toxicities that are expected to be irreversible but are stable under medical management (e.g., hypothyroidism controlled with replacement therapy, hypertension controlled to <160/100 mmHg with antihypertensive medications).

    排除标准第 22 条

    Incomplete recovery from prior surgery, or having undergone any major surgery within 4 weeks before the first dose of study drug.

    排除标准第 23 条

    Any chemotherapy or small-molecule targeted therapy within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of study drug, without delayed toxicities, with the exception of:

    排除标准第 39 条

  4. ECOG performance status of 0 or 1 (Eastern Cooperative Oncology Group).

    入选标准第 26 条

  5. Hemoglobin ≥ 90 g/L;

    入选标准第 10 条

    Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L;

    入选标准第 11 条

    Platelet count ≥ 100 × 10⁹/L;

    入选标准第 12 条

    Eosinophils < 1.5 × upper limit of normal (ULN).

    入选标准第 13 条

    Total bilirubin ≤ 1.5 × ULN (patients with total bilirubin > 1.5 × ULN are allowed if conjugated bilirubin ≤ ULN);

    入选标准第 15 条

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN;

    入选标准第 16 条

    Serum creatinine ≤ 1.5 × ULN **or** creatinine clearance (CCr) ≥ 45 mL/min, calculated by the Cockcroft-Gault formula using actual body weight;

    入选标准第 17 条

    International normalized ratio (INR) ≤ 1.5 × ULN (≤ 3 × ULN if on stable anticoagulation therapy);

    入选标准第 20 条

    Partial thromboplastin time (PTT) or activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (≤ 3 × ULN if on stable anticoagulation therapy).

    入选标准第 21 条

  6. At least one measurable lesion as defined by RECIST v1.1 for solid tumors.

    入选标准第 25 条

  7. Known human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, or active tuberculosis.

    排除标准第 30 条

    Patients who are anti-HBc (+), HBsAg (-), anti-HBs (-), and have undetectable HBV viral load do not require prophylactic antiviral treatment but must be closely monitored for HBV reactivation.

    排除标准第 32 条

    Any other malignancy diagnosed within 5 years before the first dose of study drug, except for adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, carcinoma in situ that has been completely resected, and localized prostate cancer or papillary thyroid carcinoma that has been cured by radical surgery.

    排除标准第 36 条

  8. Pregnant or breastfeeding women, or women planning to become pregnant before the first dose of study drug, during study treatment, or within 6 months after the last dose.

    排除标准第 1 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07361991,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Signed informed consent: The patient must voluntarily sign a written informed consent form and be able to comply with the visit schedule and procedures specified in the protocol.
  2. Age: 18 to 75 years (inclusive), male or female.
  3. Diagnosis and prior therapy:
  4. Histologically confirmed advanced gastric or gastroesophageal junction adenocarcinoma (GC or GEJC).
  5. Disease progression or intolerance after prior first-line systemic antitumor therapy including immunotherapy.
  6. Primary immune resistance: best response during immunotherapy is stable disease (SD) lasting < 12 weeks, or progressive disease (PD).
  7. Acquired immune resistance:
  8. For patients with PD on immunotherapy: best response during treatment is complete response (CR), partial response (PR), or SD lasting ≥ 12 weeks; 2. For patients who discontinued immunotherapy for reasons other than disease progression and subsequently developed PD: best response during treatment is CR, PR, or SD lasting ≥ 12 weeks, and the interval between last immunotherapy dose and PD is ≤ 6 months.
  9. Baseline hematology (within 7 days before first dose of study drug) must meet all of the following:
  10. Hemoglobin ≥ 90 g/L;
  11. Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L;
  12. Platelet count ≥ 100 × 10⁹/L;
  13. Eosinophils < 1.5 × upper limit of normal (ULN).
  14. Baseline serum chemistry (within 7 days before first dose) must meet all of the following:
  15. Total bilirubin ≤ 1.5 × ULN (patients with total bilirubin > 1.5 × ULN are allowed if conjugated bilirubin ≤ ULN);
  16. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN;
  17. Serum creatinine ≤ 1.5 × ULN **or** creatinine clearance (CCr) ≥ 45 mL/min, calculated by the Cockcroft-Gault formula using actual body weight;
  18. Serum albumin ≥ 32 g/L.
  19. Baseline coagulation function (within 7 days before first dose) must meet all of the following:
  20. International normalized ratio (INR) ≤ 1.5 × ULN (≤ 3 × ULN if on stable anticoagulation therapy);
  21. Partial thromboplastin time (PTT) or activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (≤ 3 × ULN if on stable anticoagulation therapy).
  22. Baseline urinalysis (within 7 days before first dose)must meet one of the following:
  23. Urine protein (UPRO) < 2+ by dipstick, **or**
  24. 24-hour urine protein < 1 g.
  25. At least one measurable lesion as defined by RECIST v1.1 for solid tumors.
  26. ECOG performance status of 0 or 1 (Eastern Cooperative Oncology Group).
  27. Estimated life expectancy ≥ 3 months.
  28. Contraception: Women of childbearing potential and men whose partners are women of childbearing potential must agree to use effective contraception throughout the treatment period and for 6 months after the last dose of study treatment.

排除标准:Exclusion Criteria:

  1. Pregnant or breastfeeding women, or women planning to become pregnant before the first dose of study drug, during study treatment, or within 6 months after the last dose.
  2. History of active thrombosis, deep venous thrombosis, or pulmonary embolism within 4 weeks before the first dose of study drug, unless adequately treated and considered clinically stable by the investigator.
  3. Clinically significant cardiovascular or cerebrovascular disease, including but not limited to:
  4. Ventricular arrhythmias or other uncontrolled arrhythmias requiring medical intervention (e.g., anti-arrhythmic therapy);
  5. Severe conduction abnormalities (e.g., third-degree atrioventricular block);
  6. QT interval corrected by Fridericia (QTcF) ≥ 480 ms;
  7. Uncontrolled arterial hypertension despite optimal medical therapy (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg);
  8. History of myocarditis;
  9. Current congestive heart failure requiring treatment;
  10. Left ventricular ejection fraction (LVEF) < 50%;
  11. New York Heart Association (NYHA) class III or IV heart failure;
  12. Acute coronary syndrome (including myocardial infarction or unstable angina), coronary angioplasty, or stent implantation within 6 months prior to the first dose;
  13. Cerebrovascular accident or transient ischemic attack within 6 months prior to the first dose;
  14. Known active seizure disorders.
  15. Interstitial lung disease, pulmonary fibrosis, pneumoconiosis, drug-induced pneumonitis, radiation pneumonitis, or other forms of restrictive lung disease that require corticosteroids or other treatment, or a history of severely impaired pulmonary function.
  16. History of atopic constitution, asthma, or atopic dermatitis.
  17. Clinically significant pleural effusion, ascites, or pericardial effusion requiring repeated drainage or associated with significant symptoms.
  18. Active autoimmune disease requiring systemic treatment (e.g., disease-modifying agents, corticosteroids, or immunosuppressive drugs) within 2 years prior to the first dose of study drug. Replacement therapy (e.g., thyroxine, insulin, or physiological replacement doses of corticosteroids for adrenal or pituitary insufficiency) is not considered systemic treatment.
  19. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
  20. Known hypersensitivity or allergy to study drugs or any of their excipients.
  21. History of significant toxicities related to prior immune checkpoint inhibitor therapy that required permanent discontinuation of that treatment.
  22. Unresolved toxicities from prior antitumor therapies > Grade 1 (based on NCI CTCAE), with the exception of the following: persistent Grade 2 alopecia, peripheral neuropathy, hypomagnesemia, or other toxicities that are expected to be irreversible but are stable under medical management (e.g., hypothyroidism controlled with replacement therapy, hypertension controlled to <160/100 mmHg with antihypertensive medications).
  23. Incomplete recovery from prior surgery, or having undergone any major surgery within 4 weeks before the first dose of study drug.
  24. Active, uncontrolled bleeding or known bleeding diathesis.
  25. Major gastrointestinal diseases or conditions within 6 months prior to the first dose, including:
  26. History of inflammatory bowel disease;
  27. ≥ Grade 2 diarrhea occurring within 2 weeks before the first dose;
  28. Radiation enteritis.
  29. Uncontrolled tumor-related pain or symptomatic hypercalcemia at screening.
  30. Known human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, or active tuberculosis.
  31. Patients who are HBsAg-positive and/or hepatitis B core antibody (HBcAb)-positive must have HBV DNA testing. Patients with HBV DNA ≤ 2.5 × 10³ copies/mL or ≤ 500 IU/mL or below the lower limit of detection may be enrolled. HBsAg-positive patients should receive antiviral therapy against HBV throughout study treatment to prevent viral reactivation.
  32. Patients who are anti-HBc (+), HBsAg (-), anti-HBs (-), and have undetectable HBV viral load do not require prophylactic antiviral treatment but must be closely monitored for HBV reactivation.
  33. Patients with positive HCV serology but negative HCV RNA or HCV RNA below the lower limit of detection may be enrolled.
  34. Patients who have completed HCV treatment and have undetectable viral load may be enrolled.
  35. Severe or uncontrolled infection, infection requiring systemic intravenous antibiotics, or fever of unknown origin > 38°C within 2 weeks prior to the first dose of study drug.
  36. Any other malignancy diagnosed within 5 years before the first dose of study drug, except for adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, carcinoma in situ that has been completely resected, and localized prostate cancer or papillary thyroid carcinoma that has been cured by radical surgery.
  37. **Prohibited medications and treatments** (patients must not receive any of the following):
  38. IL-2/IL-15-based cytokine therapies. Use of IL-2/IL-15 as a component of adoptive cell therapy or as immune modulation in immunocompromised patients is allowed.
  39. Any chemotherapy or small-molecule targeted therapy within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of study drug, without delayed toxicities, with the exception of:
  40. Use of nitrosourea agents or mitomycin C within 6 weeks prior to the first dose is prohibited.
  41. Any antibody therapy within 4 weeks prior to the first dose of study drug; 4) Participation in any interventional clinical trial involving medical devices or other therapeutic interventions within 2 weeks prior to the first dose; 5) Palliative radiotherapy within 2 weeks prior to the first dose; 6) Live vaccines for prevention of infectious diseases within 4 weeks prior to the first dose; 7) Immunosuppressive or systemic corticosteroid therapy (> 10 mg/day prednisone or equivalent) within 2 weeks prior to the first dose of study drug; 8) Traditional Chinese medicines with definite antitumor effects within 1 week prior to the first dose.
  42. History of significant toxicities related to prior paclitaxel therapy that required permanent discontinuation of that treatment, or any contraindications to study drugs that, in the opinion of the investigator, preclude safe administration of the study treatment.
  43. Any disease, treatment, laboratory abnormality, or history of drug abuse which, in the opinion of the investigator, may compromise patient safety, interfere with informed consent, affect patient compliance, or interfere with the evaluation of the safety of the study drug.
  44. Psychiatric illness, altered mental status, or history of substance abuse that may interfere with the patient's ability to understand the informed consent process and/or complete required study assessments.
  45. Any other condition that, based on known or foreseeable circumstances, in the investigator's judgment would make the patient unable to comply with the protocol requirements.

引自 ClinicalTrials.gov, NCT07361991, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07361991,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07361991